CHENGDU, Chine, 10 février 2025 /PRNewswire/ — Keymed Biosciences (HKEX : 02162) a annoncé aujourd’hui que la National Medical Products Administration (la « NMPA ») de Chine a récemment approuvé la demande supplémentaire de nouveau médicament (la « sNDA ») pour le Stapokibart (anticorps…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.